Month: August 2021

C4 Therapeutics Announces FDA Orphan Drug Designation for CFT7455 for the Treatment of Multiple Myeloma

08/17/2021

Excerpt from the Press Release: WATERTOWN, Mass., Aug. 11, 2021 (GLOBE NEWSWIRE) — C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to CFT7455…

Read More

Moderna Doubles Kids Vaccine Trial Group After FDA Request

08/17/2021

Excerpt from the Press Release: Moderna Inc. plans to double enrollment in a trial of its Covid vaccine in children under age 12, following a request from U.S. regulators to collect additional safety data. Moderna’s study will enroll an estimated 13,275 participants ages 6 months up to 12 years old, according to a listing on the clinicaltrials.gov website. In a…

Read More

Bristol Myers Squibb and Five Leading Historically Black Colleges and Universities Launch Tomorrow’s Innovators to Create Custom Biopharma Educational Programming and Increase Recruitment of Black Talent in the Biopharma Industry

08/16/2021

Excerpt from the Press Release: PRINCETON, N.J.–(BUSINESS WIRE)–Despite representing roughly 12% of the U.S. adult population, in biopharma, Black professionals account for just 7% of the total workforce and 3% of executive teams. Today, in an initiative designed to increase access to and awareness of the biopharma industry among Black talent and build a diverse talent…

Read More

Otsuka Awarded Grant for Phase 2 Trial Combining Novel Anti-Tuberculosis Compound OPC-167832 with Delamanid and Bedaquiline

08/13/2021

Excerpt from the Press Release: PRINCETON, N.J.–(BUSINESS WIRE)–Otsuka Pharmaceutical Development & Commercialization, Inc. (Otsuka), a subsidiary of Otsuka Pharmaceutical Co., Ltd., announces that it has been awarded a grant for up to $17.8 million from the Bill & Melinda Gates Foundation. This will enable Otsuka to advance clinical trials of its investigational compound OPC-167832, in…

Read More

Trillium Therapeutics Announces Dosing of First Patient in Phase 1b/2 Study of TTI-622 in Combination With Azacitidine in TP53-Mutated Acute Myeloid Leukemia

08/13/2021

Excerpt from the Press Release: CAMBRIDGE, Mass., Aug. 09, 2021 (GLOBE NEWSWIRE) — Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has dosed the first TP53-mutated acute myeloid leukemia (AML) patient with TTI-622 (SIRPα-IgG4 Fc), an investigational checkpoint inhibitor of the innate immune…

Read More

Thermo Fisher Scientific Updates Customizable TaqMan SARS-CoV-2 Mutation Panel to Detect Delta and Lambda Variants

08/13/2021

Excerpt from the Press Release: CARLSBAD, Calif., Aug. 9, 2021 /PRNewswire/ — Thermo Fisher Scientific, the world leader in serving science, today announced it has updated its Applied Biosystems TaqMan SARS-CoV-2 Mutation Panel to detect the Delta and Lambda strains. First launched in March 2021, the research panel features a customizable menu of verified real-time PCR assays for identification of…

Read More

Verseon Nominates VE-4840 as Primary Drug Candidate for Oral Prophylaxis and Treatment of Diabetic Eye Disease

08/12/2021

Excerpt from the Press Release: FREMONT, Calif., Aug. 5, 2021 /PRNewswire/ — Verseon today announced that VE-4840 will advance as the company’s primary diabetic retinopathy (DR) development candidate after it passed preliminary toxicology studies. Orally administered VE-4840 has also demonstrated significant reduction of diabetes-induced retinal vascular permeability (RVP) in vivo. These results, along with its excellent oral pharmacokinetics…

Read More

Updated Overall Survival Data and Biomarker Results from Sintilimab ORIENT-11 Study in First-Line Nonsquamous Non-Small Cell Lung Cancer Published in the Journal of Thoracic Oncology

08/12/2021

Excerpt from the Press Release: SAN FRANCISCO and SUZHOU, China, Aug. 5, 2021 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, and Eli Lilly and Company (NYSE: LLY) today announced new and updated data from the ORIENT-11…

Read More

Akston Biosciences Doses First Subjects in Phase II Clinical Trial of Second-Generation Protein Subunit COVID-19 Vaccine

08/12/2021

Excerpt from the Press Release: BEVERLY, Mass.–(BUSINESS WIRE)–Akston Biosciences Corporation, a developer of new classes of biologic therapeutics, announced today that the first participants have been dosed in a Phase II open-label trial of AKS-452, its protein subunit COVID-19 vaccine candidate. Fifty-two volunteers will receive either one- or two-dose regimens as part of the Phase II…

Read More

Radical Reads: The First Canadian AI and Healthcare Market Map

08/11/2021

Excerpt from the Press Release: Digital healthcare adoption has accelerated since the onset of the pandemic. In the first half of 2021, approximately $14.7B was invested in digital healthcare in the US, surpassing the total amount invested in 2020 (~$14B). Building on a world-class talent pool, AI startups are also booming in Canada with ~$1.4B raised in the first 6…

Read More